Area of research
Neurology · Physiology
Research interest
Research interests include Neuroscience, LRRK2, Parkinson's disease, Disease, Biology, and Cell biology.
Nuclear ASC speck formation in microglia is associated with inflammasome priming and is exacerbated in LRRK2-G2019S Parkinson’s disease
Duodenal <scp>alpha‐Synuclein</scp> Pathology and Enteric Gliosis in Advanced Parkinson's Disease
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease
α-Synuclein Toxicity in Drosophila melanogaster Is Enhanced by the Presence of Iron: Implications for Parkinson’s Disease
Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson’s disease
LRRK2 as a target for modulating immune system responses
Trafficking of the glutamate transporter is impaired in LRRK2-related Parkinson’s disease
The potential convergence of NLRP3 inflammasome, potassium, and dopamine mechanisms in Parkinson’s disease
Synapsin III gene silencing redeems alpha-synuclein transgenic mice from Parkinson's disease-like phenotype
The Roc domain of LRRK2 as a hub for protein-protein interactions: a focus on PAK6 and its impact on RAB phosphorylation
DJ-1 promotes energy balance by regulating both mitochondrial and autophagic homeostasis
Parkinson’s Disease–Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance
<scp>α‐Synuclein</scp> evokes <scp>NLRP3</scp> inflammasome‐mediated <scp>IL</scp>‐1β secretion from primary human microglia
Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges
Inhibition of Ceramide Synthesis Reduces α-Synuclein Proteinopathy in a Cellular Model of Parkinson’s Disease
Copper Ions and Parkinson’s Disease: Why Is Homeostasis So Relevant?
COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
Nuclear Factor-κB Dysregulation and α-Synuclein Pathology: Critical Interplay in the Pathogenesis of Parkinson’s Disease
Extracellular clusterin limits the uptake of α‐synuclein fibrils by murine and human astrocytes
Semisynthetic and Enzyme‐Mediated Conjugate Preparations Illuminate the Ubiquitination‐Dependent Aggregation of Tau Protein
Semisynthetic Modification of Tau Protein with Di-Ubiquitin Chains for Aggregation Studies
Immunization therapies for Parkinson’s disease: state of the art and considerations for future clinical trials
Impaired dopamine metabolism in Parkinson’s disease pathogenesis
Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils
Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
Determination of ATP, ADP, and AMP Levels by Reversed-Phase High-Performance Liquid Chromatography in Cultured Cells
USP14 inhibition corrects an in vivo model of impaired mitophagy
Diabetes Mellitus as a Risk Factor for Parkinson’s Disease: a Molecular Point of View
Dopamine Oxidation Products as Mitochondrial Endotoxins, a Potential Molecular Mechanism for Preferential Neurodegeneration in Parkinson’s Disease
Superoxide Radical Dismutation as New Therapeutic Strategy in Parkinson’s Disease